AZ and BMS diabetes drug needs more data
January 20, 2012Research and Development, Sales and Marketing AstraZeneca, BMS, FDA approvals, diabetes
AstraZeneca and Bristol-Myers Squibb must supply more data on their diabetes treatment dapagliflozin, the FDA says.Currently being developed as monotherapy, …
Novartis starts late-stage biosimilar trials for Amgen drugs
January 19, 2012Research and Development, Sales and Marketing Amgen, Neulasta, Neupogen, Novartis
Novartis has begun Phase III biosimilar trials to copycat two of Amgen’s neutropenia drugs. The studies, which are being undertaken …
Chief operating officer appointed to Clinigen’s services division
January 19, 2012Business Services, Medical Communications, Research and Development, Sales and Marketing Clinigen, Shaun Chilton
Clinigen Group, a global specialty pharma services and products business, has appointed Shaun Chilton as its new chief operating officer …
Takeda to cut 2,800 jobs
January 19, 2012Business Services, Research and Development, Sales and Marketing Nycomed, Takeda, job cuts
Takeda has announced plans to significantly reduce its global headcount over the next four years following its merger with Nycomed. …
Astellas Pharma Europe appoints Mike Crooks to head up its UK operations
January 19, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas Pharma, Mike Crooks
Astellas Pharma Europe, the European subsidiary of Tokyo-based Astellas Pharma, has appointed Mike Crooks as its new UK general manager. …
Nurses come out against Health Bill
January 19, 2012Sales and Marketing NHS, RCN, health bill, reforms
The union representing nurses and midwives in the UK has formally come out against the government’s health reform Bill. The …
Bayer’s colorectal cancer drug increases survival
January 19, 2012Research and Development, Sales and Marketing Bayer, colectoral cancer, regorafenib
Bayer and Onyx’s colorectal cancer drug regorafenib increased overall survival for late-stage patients, according to new data. The Phase III …
Lucentis approved in China
January 18, 2012Sales and Marketing China, Galvus, Lucentis, Novartis, em, emerging markets
Novartis’ eye treatment Lucentis has gained approval in China, and the firm has also launched its diabetes drug Galvus in …
Lundbeck gets award for manufacturing excellence
January 18, 2012Manufacturing and Production Lundbeck, Shingo, manufacturing
Efforts by Lundbeck to boost the productivity of its manufacturing operations have borne fruit, with the company cutting costs by …
Former Bristol-Myers Squibb man becomes head of Savient Europe
January 18, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Savient
Savient Pharmaceuticals has appointed David Veitch as the new president of its European division. Veitch joins the specialist biopharma firm …
Pfizer pulls plug on Alzheimer’s drug
January 18, 2012Research and Development, Sales and Marketing Medivation, Pfizer, dimebon
Pfizer and Medivation have written off their Alzheimer’s candidate dimebon after another Phase III failure. The firms said a 12-month …
Countdown to PM Society Advertising Awards begins
January 18, 2012Medical Communications, Sales and Marketing PM Society Advertising Awards, pm society
The Pharmaceutical Marketing Society’s Advertising Awards, one of the most significant dates in the UK pharma industry calendar, are approaching …
Novartis reverses plant closure decision
January 18, 2012Manufacturing and Production, Research and Development, Sales and Marketing Basel, Diovan, Novartis, Nyon, closure, job cuts
Novartis has said it will not close down a plant in Switzerland that had been due for closure, and has …
BMJ blasts Roche for withholding Tamiflu data
January 18, 2012Research and Development, Sales and Marketing BMJ, EMA, Roche, Tamiflu, WHO
Roche is still withholding Tamiflu data from researchers, claims the British Medical Journal. Two years after Roche said it would …
The work of NICE International
January 17, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kalipso Chalkidou, NICE
NICE, or the National Institute for Health and Clinical Excellence, to give it its full title, is world famous for …
CoreLab Partners opens office in Tokyo, Japan
January 17, 2012Research and Development
Princeton, NJ January 17, 2012 – Signaling a further commitment to expand its business model in the Pacific Rim and …
Avastin now available in UK for ovarian cancer
January 17, 2012Sales and Marketing Cancer, Cancer Drugs Fund, NICE, Roche, avastin
Roche’s Avastin is now available as a treatment for women with ovarian cancer in the UK. Avastin (bevacizumab) can now …
Government spends £100 million on winter care
January 17, 2012Sales and Marketing CCG, PCTs, government, health bill
The government is to give doctors in Clinical Commissioning Groups (CCGs) an extra £100 million to spend on improving patient …
Oxford BioTherapeutics appoints C. Glenn Begley as a senior clinical advisor
January 17, 2012Business Services, Research and Development, Sales and Marketing C. Glenn Begley, Oxford Biotherapeutics
Oxford BioTherapeutics has appointed C. Glenn Begley as a senior clinical advisor and non-executive director of the firm. Dr Begley, …
Lundbeck launches bipolar drug Sycrest in the UK
January 17, 2012Sales and Marketing Lundbeck, Saphris, Sycrest, zyprexa
Lundbeck has launched Sycrest in the UK for the treatment of acute attacks of bipolar I disorder. Sycrest (asenapine) is …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
